The Full
Spectrum

Salvia divinorum's active compound, salvinorin A, is the only known naturally occurring κ-opioid receptor (KOR) agonist — a completely different mechanism from all other classical psychedelics, which act on serotonin receptors. This pharmacological uniqueness means it has no cross-tolerance with other psychedelics and produces effects qualitatively unlike any other known substance. It is active at approximately 200 micrograms — making it the most potent naturally occurring psychedelic by weight.

The κ-opioid receptor is involved in pain modulation, dissociation, mood, and perception. KOR agonism in animals produces dysphoria and dissociation. In humans at psychedelic doses, salvinorin A produces what can only be described as a complete deconstruction and reassembly of experienced reality — often without the emotional warmth of classical psychedelics.

Salvia divinorum grows natively in the Sierra Mazateca mountains of Oaxaca, Mexico. The Mazatec curandera María Sabina and other healers used it as a "lesser" sacrament compared to mushrooms — primarily for divination and healing in cases where the full mushroom ceremony was inappropriate. It was consumed by eating fresh leaves or drinking leaf tea — producing mild, divinatory experiences different from the overwhelming effect of smoked concentrated extract.

Gordon Wasson and Albert Hofmann encountered it in Mazatec communities in 1962. Hofmann later isolated salvinorin A as the active compound — completing his lifelong arc from lysergic to κ-opioid chemistry.

The κ-opioid receptor system is deeply implicated in depression, addiction, and pain — making salvinorin A an important research tool and potential therapeutic lead. Non-psychedelic KOR agonists (which do not penetrate the brain) are being developed as peripheral analgesics. Brain-penetrating KOR modulators are being investigated for depression resistant to standard treatments. Salvinorin A's unique pharmacology has made it one of the most studied compounds in contemporary neuropharmacology.

Kratom's unique dose-dependent profile stems from its alkaloid mixture. Mitragynine (the primary alkaloid) is an adrenergic agonist at low doses — producing stimulation, focus, and mood elevation. At higher doses, it and its potent metabolite 7-hydroxymitragynine act as partial μ-opioid receptor agonists — producing analgesia, sedation, and euphoria. 7-OH-mitragynine is extraordinarily potent — approximately 13x more potent than morphine at the μ-opioid receptor by weight.

Critically, kratom alkaloids appear to be "biased agonists" — activating μ-opioid receptors through G-protein pathways (which produce analgesia) while having reduced activity at β-arrestin pathways (which produce respiratory depression and constipation). This biased agonism is exactly what pharmaceutical companies have sought to engineer in "safer opioids" — and kratom may have achieved it naturally.

Thousands of individuals have reported using kratom to self-taper from opioid dependence — managing withdrawal symptoms without entering a formal treatment program. Survey data finds that a significant proportion of kratom users are former opioid users, and many credit it with preventing overdose death. No confirmed kratom-only overdose deaths have been documented in the scientific literature, though combination with other depressants increases risk substantially.

The DEA attempted emergency Schedule I scheduling in 2016 — an effort reversed after an unprecedented public comment campaign, with over 23,000 comments opposing the scheduling. The plant remains in a regulatory gray zone, with ongoing FDA enforcement actions against adulterated products.

Nymphaea caerulea (Blue Lotus) is depicted in ancient Egyptian art in contexts that suggest ritual consumption dating to at least 1350 BCE — found in Tutankhamun's tomb, depicted in scenes from the Book of the Dead, and carved into the pillars of Karnak. The flowers were macerated in wine for ceremonial use — creating an entheogenic preparation that combined the alkaloids of the lotus with the disinhibiting effects of alcohol.

Egyptologist Lyn Green and archaeobotanist David Sherrat have documented the case for Blue Lotus as an ancient entheogen used in funerary rituals, fertility ceremonies, and royally-sanctioned states of altered consciousness. The lotus — rising from mud to bloom above water each morning — was a central metaphor for resurrection and divine awakening.

The active compounds are primarily nuciferine (an aporphine alkaloid that acts as a dopamine D2 receptor partial agonist and antipsychotic) and nornuciferine. These interact with dopaminergic and serotonergic systems in ways that are not fully characterized. The effects are mild by contemporary standards — euphoria, relaxation, mild visual enhancement, and enhancement of dream states. There is also a documented aphrodisiac quality noted across thousands of years of use.

Combination with wine (as used historically) may enhance effects through alcohol-mediated disinhibition and altered metabolism.

Kava's effects come from 18 different kavalactones — particularly kavain, dihydrokavain, methysticin, and dihydromethysticin. These work through multiple mechanisms: blocking voltage-gated sodium channels (producing muscle relaxation and analgesia), enhancing GABA-A receptor activity (producing anxiolysis), and modulating dopamine pathways (producing mild euphoria). Unlike benzodiazepines, kavalactones do not appear to produce tolerance or dependence with traditional use patterns.

The kavalactone kavain shows anxiolytic efficacy in randomized controlled trials at doses of 150–400mg daily — producing anxiety reduction comparable to benzodiazepines without cognitive impairment, sedation, or dependence risk.

A 2013 double-blind randomized controlled trial published in the Journal of Clinical Psychopharmacology found that kava extract produced significant reduction in generalized anxiety disorder symptoms compared to placebo, with effects emerging in week two and reaching significance by week four. Crucially, it was well-tolerated with no cognitive impairment — and produced a trend toward improved sexual function rather than the sexual dysfunction common with SSRIs and benzodiazepines.

In Fiji, Vanuatu, Samoa, Tonga, and Hawai'i, kava ceremony is the central social institution — equivalent in cultural role to wine in Mediterranean culture, but consumed communally from a shared bowl in a ritual of social bonding, conflict resolution, and political decision-making. Chiefs, elders, and community members share the bowl to seal agreements and mark transitions. The kava bar is replacing the alcohol bar in harm reduction contexts across the Pacific and increasingly in US cities.

San Pedro cactus (Echinopsis pachanoi) contains mescaline as its primary psychoactive alkaloid at concentrations of approximately 0.12% fresh weight, alongside over 15 other phenethylamine and isoquinoline alkaloids including tyramine, hordenine, anhalidine, and others. This complex alkaloid mixture is believed to produce the San Pedro experience's distinctly different character from pure mescaline — softer, warmer, and more physically connected.

The cactus grows from Ecuador through Peru along the Andean cordillera. Archaeological evidence from the Chavín de Huantar temple complex dates its use to at least 1400 BCE. The Spanish named it San Pedro (Saint Peter) — the keeper of the gates of heaven — a name that inadvertently preserved it from suppression during the colonial period.

The San Pedro ceremony, led by a curandero using the cactus preparation called "wachuma," is a 12-hour healing ritual oriented around the identification and resolution of illness — physical, emotional, and spiritual. The experience is consistently described as distinctly "grandfatherly" — warm, grounded, and embodied compared to the more visionary and otherworldly quality of ayahuasca. Strong connection to the natural world, the earth, and ancestral lineage are characteristic themes.

The revival of San Pedro ceremony in contemporary healing contexts is producing a new body of observational data on its effects in trauma, depression, and chronic pain — similar to the ayahuasca data pool but with a distinctly different phenomenological character.

Peganum harmala seeds contain harmine, harmaline, and tetrahydroharmine (THH) — β-carboline alkaloids that are reversible inhibitors of monoamine oxidase (RIMAs), specifically MAO-A. By inhibiting the enzyme that normally breaks down DMT in the gut and liver, these harmala alkaloids render orally consumed DMT active — the precise mechanism of ayahuasca. This was the great discovery of ethnobotanist Richard Evans Schultes and chemist Neil McKenna: the ayahuasca vine is pharmacologically equivalent to Syrian rue.

Syrian rue was independently used in Persian, Middle Eastern, and Central Asian healing traditions — as an antidepressant, anthelmintic, and visionary medicine. TiHKAL documents harmaline and harmine as independently mildly psychoactive — producing a gentle visionary state alone before the MAOI effect becomes dangerous with other substances.

Harmine and harmaline show remarkable independent neuroplastic properties. Harmine is a potent inhibitor of DYRK1A kinase — an enzyme involved in neurogenesis. Multiple studies have shown that harmine promotes the proliferation of human neural progenitor cells in vitro, suggesting direct neurogenic potential beyond its MAOI activity. This positions it as an independent candidate for research in depression, Alzheimer's, and other conditions of neurodegeneration.

THC's mechanism is unique — it acts on a receptor system that evolution apparently built to receive it. The endocannabinoid system (ECS) consists of CB1 receptors (densely expressed in the brain, particularly prefrontal cortex, hippocampus, basal ganglia, and cerebellum) and CB2 receptors (primarily in immune tissue). The endogenous ligands — anandamide and 2-AG — are "endocannabinoids," structurally related to THC. This system regulates pain, appetite, memory, immune function, and emotional processing.

THC's high affinity for CB1 receptors — particularly in the prefrontal cortex and basal ganglia — explains its characteristic effects on thought, perception, and movement. The diversity of effects across individuals reflects the remarkable variability in CB1 receptor expression and endocannabinoid tone.

FDA-approved cannabis-derived medications include dronabinol (synthetic THC, Marinol) for chemotherapy-induced nausea and AIDS wasting syndrome, nabilone (synthetic cannabinoid) for the same indications, and Epidiolex (CBD) for specific pediatric epilepsies. The clinical evidence for medical cannabis is strongest for neuropathic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity — with robust systematic review data.

Emerging research is investigating cannabis in PTSD (several veterans' studies showing symptom reduction), inflammatory bowel disease, and as an adjunct in opioid tapering protocols. Some of the most promising new research focuses on CBD's independent pharmacology — particularly its activity at TRP channels, GPR55, and 5-HT₁A receptors.

Cannabis can significantly amplify and modify psychedelic experiences when combined. CB1 activation in psychedelic states synergizes with 5-HT₂A effects — often deepening visuals and increasing psychological intensity. At high doses independently, cannabis can produce psychedelic-like experiences including mild depersonalization, visual phenomena, and profound introspection. Its combination with other psychedelics requires careful consideration — it can rescue challenging experiences or intensify them unpredictably.

CBD's pharmacology is strikingly complex for a "non-psychoactive" compound. Unlike THC, CBD has very low affinity for CB1 and CB2 receptors — it works primarily through: 5-HT₁A receptor agonism (explaining anxiolytic and antidepressant effects); TRPV1 and TRPA1 channel modulation (explaining anticonvulsant and anti-inflammatory properties); GPR55 inverse agonism; inhibition of adenosine reuptake (contributing to anti-inflammatory effects); and weak GABA-A potentiation.

It also acts as a negative allosteric modulator at CB1 receptors — meaning it reduces the effect of THC when present, explaining why high-CBD cannabis strains are less anxiety-provoking than high-THC strains.

FDA approval of Epidiolex (pharmaceutical-grade CBD) for Dravet syndrome and Lennox-Gastaut syndrome in 2018 was landmark — the first FDA approval of a plant-derived cannabinoid. Seizure reduction rates of 39–41% compared to 14–17% for placebo in pivotal trials. This approval validated cannabis as legitimate medicine after decades of Schedule I prohibition.

Emerging evidence supports CBD in anxiety disorders (particularly social anxiety disorder, where several RCTs show significant efficacy), psychosis (as an adjunct in schizophrenia — a paradoxical finding given THC's psychosis risk), and as an opioid-sparing analgesic. The PTSD research combining CBD with psychotherapy is particularly active and promising.

5-MeO-DMT is the methoxy-substituted cousin of N,N-DMT — a single oxygen atom that fundamentally transforms the experience from a populated visionary journey into a complete, featureless dissolution of self. It is found naturally in the venom of Bufo alvarius (Sonoran Desert toad) and in numerous plant species including Anadenanthera peregrina — used by indigenous cultures of South America in ceremonial snuffs for millennia.

Pharmacologically, it is a potent agonist at 5-HT₂A and 5-HT₁A receptors, with particularly high affinity for 5-HT₁A — which may account for the stark qualitative difference from DMT. The Sigma-1 receptor activation provides neuroprotective and neuroplastic effects similar to its close relative.

Unlike N,N-DMT's rich geometric entities and populated landscapes, 5-MeO-DMT produces what Stanislav Grof termed "unitive consciousness" — the complete merger of subject and object. Most users report no visuals whatsoever. What remains is pure, undifferentiated awareness — often described simultaneously as void and as overwhelming presence. Fear is common in the first moments; surrender is the only functional response. Many describe emerging with the most profound sense of love and peace of their lives.

Onset at smoked doses is near-instantaneous. The experience is often described as "too much, too fast, too real" — significantly more intense than N,N-DMT despite the shorter chemical distance. Integration takes considerable time; the experience can be disorienting for days.

A landmark study in Frontiers in Psychiatry (2019) documented 5-MeO-DMT administered in naturalistic ceremonial settings producing rapid and sustained reductions in anxiety and depression — with improvements persisting at 4-week follow-up. The Stanford ibogaine veterans study (2024) often pairs 5-MeO-DMT with ibogaine in the MISTIC protocol, which produced 100% PTSD response rates in 30 combat veterans.

PTSD treatment research is especially active. The proposed mechanism involves rapid 5-HT₁A activation producing a "reset" of fear-conditioned neural circuits in the amygdala — essentially a biological reprieve from the hypervigilance state that defines PTSD.

4-AcO-DMT (O-acetylpsilocin) was first synthesized by Albert Hofmann and Franz Troxler in 1963 — just a few years after Hofmann's isolation of psilocybin. It is the acetyl ester of psilocin, and is widely believed to act primarily as a prodrug — rapidly deacetylated to psilocin in the body by plasma esterases. This would make it pharmacologically nearly identical to psilocybin itself, though at slightly different potency ratios.

Whether it also has activity in its native form remains pharmacologically unsettled — some subjective reports suggest a slightly "smoother" quality than psilocybin, which may reflect metabolic differences or direct receptor activity.

Users consistently describe the 4-AcO-DMT experience as virtually identical to psilocybin mushrooms — warm, organic, emotionally resonant visuals; deep introspection; periods of profound compassion for self and others; and a rich afterglow. The synthetic form offers precise dosing that mushrooms cannot. At higher doses, full ego dissolution and mystical-type experiences occur with similar frequency to psilocybin.

Reports frequently describe a softer, more forgiving character compared to LSD — more likely to produce emotional catharsis than analytical insight, more likely to generate wonder than paranoia. Often associated with deep appreciation of music, art, and natural environments.

Because 4-AcO-DMT is believed to convert to psilocin, it theoretically carries all the therapeutic potential of psilocybin — neuroplasticity via BDNF, 5-HT₂A agonism, ego dissolution-mediated psychological flexibility. It has not been studied independently in clinical trials, but its similarity to psilocybin makes it an interesting research chemical for laboratories seeking to study psilocin pharmacokinetics.

DET (N,N-diethyltryptamine) was studied extensively by Shulgin and documented in TiHKAL. Its two ethyl groups in place of DMT's two methyl groups produce a molecule that is orally active — a striking property given DMT's complete oral inactivity without MAOIs. The mechanism of oral activity isn't fully characterized but may relate to differential MAO substrate specificity.

It was one of the earliest tryptamines clinically studied, appearing in mid-20th century psychiatric literature under the designation T-9. Early researchers were struck by its unusual combination of psychedelic and empathogenic properties.

Shulgin collected reports across multiple routes and doses. At 75mg orally: "Onset seemed to be at 40 minutes — an absolutely profound, enriching experience." At 40mg smoked: users described immediate camaraderie, heightened tactile sensitivity, and spontaneous purring with companions. At 60mg IM by early researchers: "The yellow walls had an air of medieval mood about them. A painter's eye was awakened — looking at things with an unusual conscious attention."

Across reports, DET is consistently described as more social and empathogenic than DMT — less likely to produce entity contact or reality dissolution, more likely to open emotional warmth and connection. The visual element is present but secondary to the interpersonal quality.

DET was part of a wave of tryptamine research in Eastern Europe in the 1950s and 60s. Hungarian researchers studied it in schizophrenic patients and healthy volunteers, producing detailed phenomenological reports. This research was largely lost to Western science during the Cold War, only recovered through Shulgin's archival work in TiHKAL.

4-HO-MET is a member of the 4-hydroxy tryptamine family — the same chemical class as psilocin (4-HO-DMT). The substitution of one methyl group for an ethyl group on the nitrogen produces a compound with a notably different experiential character despite similar receptor binding. It is synthesized by reacting indole with methyl ethyl oxalyl chloride and reducing the resulting amide.

Like all 4-hydroxy tryptamines, 4-HO-MET is a direct 5-HT₂A agonist — it does not require metabolic conversion and produces effects more rapidly than psilocybin. The precise pharmacological reason for its characteristically visual and euphoric character (compared to psilocybin's more introspective tendency) remains unexplained — possibly due to differential 5-HT₂C or 5-HT₁A activity.

4-HO-MET is consistently described as one of the most visually spectacular tryptamines — producing vivid, richly colored, rapidly shifting geometric patterns that many users find more aesthetically satisfying than psilocybin. The emotional content is lighter and more playful than the heavy introspective quality often associated with mushrooms. It is frequently described as "euphoric" and "fun" — an unusual word in the tryptamine vocabulary — without sacrificing depth at higher doses.

Music becomes extraordinarily enhanced. Body feel is generally pleasant, without the nausea that can accompany mushroom use. The afterglow is mild and positive.

Bufotenine (5-hydroxy-DMT) is the 5-hydroxy analog of DMT — with the hydroxyl group at the 5-position instead of DMT's absent substitution or 5-MeO-DMT's methoxy. It occurs naturally in Anadenanthera peregrina (yopo/cohoba beans) — sacred to numerous South American indigenous cultures — in Bufo alvarius toad venom, and is produced endogenously in the human body. TiHKAL documents its role as the primary alkaloid in yopo beans alongside DMT and 5-MeO-DMT.

It was long dismissed by Western science as a peripheral vasoconstrictor with no psychedelic activity — a classification based on flawed early studies using peripheral administration routes. More careful research has established genuine psychedelic activity when bufotenine reaches the brain.

Contemporary reports describe a short, powerful experience with remarkable chromatic hallucinations — deep purple, green, and gold color floods — and a strong physical component including cardiovascular stimulation. At lower doses, users report visual enhancement and mood elevation reminiscent of DMT but more "earthy." At breakthrough doses, the experience shares features with DMT but with a distinctive quality often described as "ancient" or "ancestral."

The yopo ceremony — which includes bufotenine-rich seeds blown into the nasal passage through ceremonial pipes — has been practiced for at least 4,000 years in South America. The contemporary revival of this ceremony in healing contexts is producing observational data on its therapeutic potential.

AL-LAD (6-allyl-6-nor-LSD) is entry #1 in TiHKAL, synthesized from nor-LSD by N-allylation with allyl bromide. Shulgin documented the synthesis in characteristic detail, noting a yield of 88% as white crystalline product with mp 88–90°C. It is an LSD analog in which the two N-diethyl substituents of LSD are replaced by a 6-allyl and 6-nor substitution pattern — producing a compound with broadly similar but distinctly different pharmacology.

At doses of 80–160 micrograms (similar to LSD dosing), AL-LAD produces effects lasting 6–8 hours — roughly half the duration of LSD. The shorter window and characteristically lighter, more visual, and more playful nature compared to LSD have made it popular in the research chemical community.

Reports consistently characterize AL-LAD as more visual and less introspective than LSD — producing colorful, playful, beautiful visuals with a lighter psychological weight. The emotional content is more uniformly positive and euphoric; the likelihood of difficult psychological content is reduced compared to LSD. Music enhancement is pronounced. Many describe it as the "gentle" version of the LSD experience — suitable for nature environments and creative work.

The shorter duration (6–8 hours versus LSD's 10–14) is frequently mentioned as a practical advantage for users who find LSD's length difficult to accommodate.

2C-B was synthesized by Alexander Shulgin in 1974 and became his personal favorite among his hundreds of compounds. Documented in PiHKAL as entry #20, he described it as "perhaps the most ideal psychedelic" — noting its remarkable dose-sensitivity, clean pharmacology, and the extraordinary integration of sensory and empathogenic qualities. The bromo substitution at the 4-position of the mescaline-related 2,5-dimethoxyphenethylamine scaffold produces a potent but controllable compound.

It binds with high affinity to 5-HT₂A and 5-HT₂C receptors, with additional activity at dopaminergic systems explaining its stimulant-adjacent character. It has uniquely steep dose-response — 12mg produces mild effects, 20mg produces full psychedelia. The two-milligram difference in the middle of that range is experientially significant.

2C-B produces extraordinarily beautiful visual phenomena — richly colored, organic, flowing — combined with MDMA-adjacent emotional opening and pronounced sensory enhancement. Touch becomes extraordinary. Music becomes architecturally visible. The combination of visual psychedelia with heightened sensuality is unique to 2C-B among major psychedelics.

Shulgin's PiHKAL reports from the compound's early testing circle describe it consistently as warm, gentle, and erotic at lower doses; fully psychedelic at higher. The "body load" is minimal compared to many phenethylamines. The 4–6 hour window is considered a feature — enough depth without the exhausting length of LSD or mescaline.

Before its scheduling in the US in 1995, 2C-B was used therapeutically by a network of psychedelic therapists as an alternative and adjunct to MDMA — particularly for couples therapy and sexual trauma work, where its combination of empathy and sensory enhancement was considered uniquely suited. Underground therapeutic use continues in global harm reduction contexts.

PiHKAL #29 documents 2C-E (4-ethyl-2,5-dimethoxyphenethylamine), with Shulgin rating it among the most significant compounds in the phenethylamine series. The ethyl substitution in place of 2C-B's bromine produces a compound of greater depth and demanding character. Shulgin's own report at 16mg described the experience as difficult to yield to — producing "a constant urge to be doing something" alongside intense visual phenomena.

2C-E shows potent 5-HT₂A agonism. Its extended duration (8–12 hours) sets it apart from most 2C compounds and contributes to its reputation as one of the most challenging phenethylamines.

2C-E is consistently described as one of the most visually stunning and intellectually demanding psychedelics. Where 2C-B produces warmth, 2C-E produces a cool, crystalline intensity — more LSD-like in its analytical, architectural character. The visuals are extraordinarily detailed and geometric. The introspection is deep and sometimes uncomfortable. Many experienced psychedelic users rate it among their most significant experiences; many beginners find it overwhelming.

DOM (4-methyl-2,5-dimethoxyamphetamine) was synthesized by Alexander Shulgin and documented in PiHKAL as compound #68. At the 1967 San Francisco Summer of Love, large quantities were distributed as "STP" — a name Shulgin later learned stood for "Serenity, Tranquility, Peace." The tablets were massively overdosed at 10mg+, producing experiences lasting up to 30 hours. The attempt to treat overwhelmed users with chlorpromazine (Thorazine) dramatically worsened outcomes — a seminal harm reduction lesson that still reverberates.

DOM contains both the 2,5-dimethoxy phenethylamine scaffold and an amphetamine-type methyl group — making it a potent 5-HT₂A agonist with significant dopaminergic stimulant properties. The combination produces the unique quality of LSD-like psychedelia with amphetamine energy, explaining the intense physicality and extreme wakefulness.

DOM's defining feature is duration. Even at threshold doses, the experience runs 12+ hours. At active doses, 20–30 hours is reported. The character is stimulating, visually intense, and analytically complex — described as more "sharp" and "mechanical" than psilocybin or mescaline. Sleep is completely impossible during the experience.

MDA predates MDMA in both synthesis (1910) and psychedelic research. It was studied in the 1960s by researchers including Gordon Alles (who synthesized amphetamine) and Claudio Naranjo, who used it in therapeutic sessions producing remarkable results in patients. MDA releases serotonin, dopamine, and norepinephrine like MDMA, but additionally shows agonist activity at 5-HT₂A receptors — adding a genuine hallucinogenic component absent from MDMA.

The result is an experience that blends MDMA's emotional opening and empathogenic quality with visual phenomena closer to a mild psilocybin experience. Some researchers consider MDA to have been the superior therapeutic agent of the two, owing to this added introspective depth.

Claudio Naranjo conducted extensive psychotherapy sessions with MDA in Chile in the 1960s–70s, treating depression, neurosis, and existential crisis. He described it as producing "a state of increased emotional accessibility" — patients reported reaching emotional material impossible to access in conventional therapy. His work represents some of the earliest rigorous psychedelic psychotherapy, predating the current clinical renaissance by decades.

TMA-2 (2,4,5-trimethoxyamphetamine) is compound #158 in PiHKAL. Shulgin found it to be approximately twice as potent as TMA (3,4,5-trimethoxyamphetamine — the amphetamine analog of mescaline) — active at 20–40mg. The 2,4,5 substitution pattern (rather than the 3,4,5 of mescaline) produces a more stimulating compound with a higher potency-to-weight ratio.

Shulgin's personal reports from TMA-2 describe extraordinary lucidity and analytical clarity alongside mescaline-style visual phenomena — particularly color enhancement and geometric patterns. The amphetamine backbone adds sustained wakefulness and mental energy not found in mescaline itself.

Described as mescaline with amphetamine — rich color enhancement, geometric visual phenomena, and expanded consciousness paired with unusual mental energy and wakefulness. Duration is long (8–16 hours), placing it among the more demanding phenethylamines. Shulgin noted it as producing "perhaps the finest esthetic and intellectual experience" of any compound in the TMA series.

Nitrous oxide was first synthesized by Joseph Priestley in 1772 and popularized by Humphry Davy, who noted its extraordinary psychological effects in 1800 — writing that "Nothing exists but thoughts." William James, the father of American psychology, wrote extensively on his nitrous oxide experiences as producing genuine insight into the nature of consciousness. It remains the most widely used psychoactive substance after alcohol, caffeine, and tobacco.

Its mechanism involves NMDA glutamate receptor antagonism (shared with ketamine) and κ-opioid receptor agonism — producing dissociation, analgesia, and euphoria. It is still widely used in medical anesthesia and dentistry worldwide.

At mild doses: laughter, warmth, mild dissociation, and auditory distortion producing characteristic "wa-wa-wa" sound. At higher doses: complete dissociation, ego dissolution, and perception loops — moments of consciousness repeating fractally, often with a sense of having accessed a fundamental truth. The brevity means these moments are experienced as crystalline flashes rather than developed journeys.

William James described his nitrous experiences as providing the most convincing evidence he had ever encountered that "our normal waking consciousness is but one special type of consciousness, whilst all about it, parted from it by the filmiest of screens, there lie potential forms of consciousness entirely different."

Recent research has demonstrated nitrous oxide's rapid antidepressant properties — similar in mechanism to ketamine. A 2021 study in Science Translational Medicine found that a single one-hour nitrous oxide session produced significant antidepressant effects lasting two weeks in treatment-resistant depression patients. It is now being investigated as a cheaper, more accessible alternative to ketamine infusion therapy.

DXM's effects are uniquely categorized into "plateaus" based on dose: First plateau (100–200mg) — mild stimulation and psychedelia. Second plateau (200–400mg) — significant dissociation, visual disturbances, euphoria. Third plateau (400–700mg) — heavy dissociation, possible out-of-body experiences. Fourth plateau (700mg+) — complete dissociation, profound and potentially dangerous.

DXM is a Sigma-1 receptor agonist, NMDA antagonist, and serotonin reuptake inhibitor — a uniquely complex pharmacological profile. Its active metabolite dextrorphan is the primary NMDA-active species. Sigma-1 agonism produces the distinctive dissociative quality that differs subtly from ketamine.

DXM combined with quinidine (which inhibits DXM metabolism) is FDA-approved as Nuedexta for pseudobulbar affect. The combination is now being studied for major depressive disorder, with Phase 2 trials showing antidepressant effects comparable to ketamine but at far lower cost. The Sigma-1 activation may contribute independently to antidepressant and neuroprotective effects.

PCP (phencyclidine) was developed by Parke-Davis in the 1950s as Sernyl — a surgical anesthetic that produced complete anesthesia without respiratory depression. It was abandoned for medical use due to severe emergence delirium in patients recovering from anesthesia — producing agitation, confusion, and hallucinations. The subsequent development of ketamine by Calvin Stevens in 1962 was a direct response to PCP's problematic profile, with the goal of creating a shorter-acting, less severe alternative.

PCP's scientific contribution was enormous — it was through PCP and ketamine research that the NMDA glutamate receptor was identified as a key substrate of anesthesia, analgesia, and consciousness. Every modern understanding of glutamate's role in depression, psychosis, and consciousness traces directly to PCP research.

PCP produces profound analgesia — the inability to feel pain — combined with complete dissociation from reality. The combination can produce extremely dangerous behavior due to the absence of normal pain feedback and severely distorted perception. At low doses, users describe stimulation and mild euphoria; at medium doses, significant dissociation and perceptual distortion; at high doses, complete detachment from reality with amnesia. The analgesia is so profound that users have been documented sustaining severe injuries without awareness.

Datura's effects are produced by a shifting mixture of three tropane alkaloids — atropine, scopolamine (also called hyoscine), and hyoscyamine. All three are competitive antagonists at muscarinic acetylcholine receptors — blocking the cholinergic signaling that underlies both peripheral autonomic function (heart rate, salivation, digestion, pupil dilation, sweating) and central cognitive function (memory, attention, perception). The classical toxidrome is summarized by the mnemonic: "blind as a bat, mad as a hatter, red as a beet, hot as a hare, dry as a bone, the bowel and bladder lose their tone, the heart runs alone."

Atropine (dl-hyoscyamine) is the prototype — longer-acting, more peripherally active, produces the pronounced tachycardia and dilation. It is still used in medicine as an antidote for organophosphate poisoning and as a pre-anesthetic. Scopolamine is more centrally active, more sedating, and produces the characteristic profound anterograde amnesia — patients have no memory of events during the drug's peak. It is used medically for motion sickness (Transderm-Scop patches). Hyoscyamine is the levorotatory isomer of atropine and behaves similarly but with slightly different tissue distribution.

Critically, the alkaloid ratio varies enormously — between species, between plants of the same species, between parts of the same plant, between seasons, between years, even between seeds on the same seedpod. This variability is the single most dangerous feature of datura. A dose that produced an uncomfortable experience in one preparation can be lethal in the next.

Unlike psychedelics, which distort perception but generally preserve the user's sense that the distortions are produced by a drug, deliriants produce hallucinations that are perceptually indistinguishable from reality. The classic datura report involves extended conversations with phantom people — friends, family members, strangers who are not present — that the user has no idea are hallucinations at the time. Users have been documented going to work, holding conversations with co-workers who are not there, picking up objects that do not exist, smoking phantom cigarettes, and having no awareness anything is unusual.

The amnesia is profound. Users typically have fragmentary, dreamlike, or no memory of the experience. Reports are reconstructed from eyewitness accounts and the aftermath. Most reports describe the experience — retrospectively — as terrifying, confusing, physically miserable, and deeply unpleasant. Experienced psychedelic users who have tried datura overwhelmingly report they will never repeat it.

The physical toxidrome is severe and prolonged. Heart rate can exceed 150 bpm for hours. Body temperature can rise to dangerous levels (hyperthermia is a common cause of death). Inability to urinate, severe mouth dryness, blurred vision lasting days, and photophobia are standard. Peak effects last 8–12 hours; residual effects, pupil dilation, and cognitive impairment can persist 2–3 days.

Datura species appear in the ethnobotanical records of virtually every culture that encountered them — across the Americas, Europe, Asia, and Africa. But unlike ayahuasca, peyote, or mushrooms, datura is almost never described as a celebrated sacrament. It appears instead as the province of specialists — shamans, witches, sorcerers — who used it rarely, with great caution, and who warned the uninitiated in the strongest possible terms. European witch-trial records describe the "flying ointment" — datura and belladonna rendered into fat and applied to mucous membranes — used by specialists who knew the doses.

Several Indigenous North American nations used datura (the species Datura wrightii and Datura inoxia) in coming-of-age ceremonies — administered by elders in carefully measured preparations, within highly structured ritual containers, with days of recovery supervised by the community. These contexts bear no resemblance to contemporary experimentation. The fatalities and permanent psychiatric injuries that have occurred in modern recreational datura use are not a failure of the plant; they are the predictable result of removing a dangerous specialist's tool from the context that made it survivable.

Atropa belladonna contains the same tropane alkaloid mixture as datura — predominantly atropine and hyoscyamine, with variable scopolamine. The effects and risks are essentially identical to datura. Its cultural history is European rather than American: the plant takes its name from the Italian bella donna ("beautiful lady"), referring to the Renaissance practice of using dilute belladonna drops to dilate women's pupils — considered an attractive feature. The genus name Atropa comes from Atropos, the Fate who cuts the thread of life.

Belladonna was the primary ingredient in European witches' flying ointments — lard-based preparations applied to mucous membranes to bypass the nauseating effects of oral consumption and deliver the alkaloids through transdermal absorption. Confessions from the witch trials describe vivid sensations of flight, meetings with otherworldly figures, and bacchanalian revels. Modern readings treat these as the predictable content of anticholinergic delirium rather than evidence of witchcraft.

Brugmansia species are widely cultivated as ornamental trees — their large, pendulous, trumpet-shaped flowers are spectacular, and they grow easily in warm climates. They are popular in gardens from California to the Mediterranean, often planted by homeowners with no awareness of their toxicity. Every part of the plant contains tropane alkaloids in quantities sufficient to cause anticholinergic delirium, and poisonings from children and curious adults are documented annually.

Traditional use in the Andes involves small amounts added to ayahuasca brews by some shamans — a practice considered specialist-only and quite different from the primarily harmaline/DMT ayahuasca of the Amazon. It is also used topically in some folk-medicine contexts. The scopolamine-dominant alkaloid profile tends to produce more pronounced sedation and amnesia than atropine-dominant datura.